Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain - PubMed (original) (raw)
. 2011 Nov;60(Pt 11):1617-1625.
doi: 10.1099/jmm.0.033423-0. Epub 2011 Jun 23.
Affiliations
- PMID: 21700738
- DOI: 10.1099/jmm.0.033423-0
Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain
Timothy D H Woo et al. J Med Microbiol. 2011 Nov.
Abstract
In contrast to most modern pharmaceuticals, probiotics are used in many parts of the world with little or no research data on the complex system of interactions that each strain may elicit in the human body. Research on probiotics has recently become more significant, as probiotics have begun to be prescribed by clinicians as an alternative for some gut infections, especially when antibiotics are contraindicated. This study attempted to elucidate the inhibitory interaction between the Japanese probiotic strain Clostridium butyricum MIYAIRI 588 (CBM588) and the hospital pathogen Clostridium difficile, which is responsible for a large proportion of antibiotic-associated diarrhoea and colitis. CBM588 has previously shown effectiveness against C. difficile in vivo, and here it was found that the toxicity of C. difficile in in vitro co-culture with CBM588 was greatly decreased or absent. This was dependent on the inoculation ratio and was not accounted for by the small degree of growth and mRNA inhibition observed. CBM588 and its cell-free supernatant also had no effect on toxin already secreted into the culture medium, and culture of the two strains separated by a semi-permeable membrane resulted in loss of the inhibition. Therefore, it was concluded that the detoxification probably occurred by the inhibition of toxin protein production and that this required close proximity or contact between the two species. The low-pH conditions caused by organic acid secretion were also observed to have inhibitory effects on C. difficile growth, metabolism and toxicity.
Similar articles
- In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains.
Schoster A, Kokotovic B, Permin A, Pedersen PD, Dal Bello F, Guardabassi L. Schoster A, et al. Anaerobe. 2013 Apr;20:36-41. doi: 10.1016/j.anaerobe.2013.02.006. Epub 2013 Mar 5. Anaerobe. 2013. PMID: 23471038 - Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo.
Isa K, Oka K, Beauchamp N, Sato M, Wada K, Ohtani K, Nakanishi S, McCartney E, Tanaka M, Shimizu T, Kamiya S, Kruger C, Takahashi M. Isa K, et al. Hum Exp Toxicol. 2016 Aug;35(8):818-32. doi: 10.1177/0960327115607372. Epub 2015 Oct 5. Hum Exp Toxicol. 2016. PMID: 26437792 - In vitro inhibition of Clostridium difficile by commercial probiotics: A microcalorimetric study.
Fredua-Agyeman M, Stapleton P, Basit AW, Beezer AE, Gaisford S. Fredua-Agyeman M, et al. Int J Pharm. 2017 Jan 30;517(1-2):96-103. doi: 10.1016/j.ijpharm.2016.12.005. Epub 2016 Dec 5. Int J Pharm. 2017. PMID: 27923699 - Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. Goldenberg JZ, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD006095. doi: 10.1002/14651858.CD006095.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728658 Updated. Review. - Alternative strategies for Clostridium difficile infection.
Bauer MP, van Dissel JT. Bauer MP, et al. Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S51-6. doi: 10.1016/S0924-8579(09)70018-4. Int J Antimicrob Agents. 2009. PMID: 19303571 Review.
Cited by
- The Potential of Clostridium butyricum to Preserve Gut Health, and to Mitigate Non-AIDS Comorbidities in People Living with HIV.
Yang Q, Zaongo SD, Zhu L, Yan J, Yang J, Ouyang J. Yang Q, et al. Probiotics Antimicrob Proteins. 2024 Aug;16(4):1465-1482. doi: 10.1007/s12602-024-10227-1. Epub 2024 Feb 9. Probiotics Antimicrob Proteins. 2024. PMID: 38336953 Review. - The metagenomic and metabolomic profile of the gut microbes in Chinese full-term and late preterm infants treated with Clostridium butyricum.
Li H, Ma X, Li Y, Liu Q, Tian Q, Yang X, Zhou Z, Ren J, Sun B, Feng X, Zhang H, Yin X, Li H, Ding X. Li H, et al. Sci Rep. 2023 Oct 31;13(1):18775. doi: 10.1038/s41598-023-45586-2. Sci Rep. 2023. PMID: 37907561 Free PMC article. - Recombinant Lactococcus lactis Expressing Human LL-37 Prevents Deaths from Viral Infections in Piglets and Chicken.
Zhang H, Dong M, Xu H, Li H, Zheng A, Sun G, Jin W. Zhang H, et al. Probiotics Antimicrob Proteins. 2023 Sep 25. doi: 10.1007/s12602-023-10155-6. Online ahead of print. Probiotics Antimicrob Proteins. 2023. PMID: 37743432 - Comparison of clinical severity, genotype and toxin gene expression of binary toxin-producing Clostridioides difficile clinical isolates in Japan.
Matsumoto A, Yamagishi Y, Miyamoto K, Higashi S, Oka K, Takahashi M, Mikamo H. Matsumoto A, et al. Access Microbiol. 2022 Oct 20;4(10):acmi000362. doi: 10.1099/acmi.0.000362. eCollection 2022. Access Microbiol. 2022. PMID: 36415735 Free PMC article. - Probiotics as Alternatives to Antibiotics for the Prevention and Control of Necrotic Enteritis in Chickens.
Kulkarni RR, Gaghan C, Gorrell K, Sharif S, Taha-Abdelaziz K. Kulkarni RR, et al. Pathogens. 2022 Jun 16;11(6):692. doi: 10.3390/pathogens11060692. Pathogens. 2022. PMID: 35745546 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources